REGENXBIO (NASDAQ:RGNX – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Tuesday. RGNX has been the topic of a ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 13, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended ...

As the world recognizes Rare Disease Day on Feb. 28, Rockville-based biotechnology company, REGENXBIO is working to change ...

Regenxbio Inc (RGNX)股价已触及52周新低，跌至6.54美元，目前市值为3.3047亿美元，该生物科技公司正面临严峻的市场环境。根据 InvestingPro ...

周二，高盛对Regenxbio Inc. (NASDAQ: RGNX )的投资立场做出重大调整，将该股评级从"买入"下调至"中性"，并将目标价从此前的$38.00大幅下调至$14.00。根据 InvestingPro 数据显示，尽管公司整体财务健康评分为"一般"，但其当前的公允价值表明可能被低估。

ABOUT REGENXBIO Inc. REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has ...

Leerink Partners analyst Mani Foroohar maintained a Buy rating on RegenXBio (RGNX – Research Report) on February 20 and set a price target of ...

REGENXBIO (NASDAQ:RGNX – Get Free Report) is anticipated to announce its earnings results before the market opens on Tuesday, ...

Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and declining appeal in retinal diseases.

Goldman Sachs made a significant adjustment to its stance on Regenxbio Inc . (NASDAQ:RGNX), downgrading the stock from "Buy" to "Neutral" and reducing the price target dramatically to $14.00 from the ...

RegenXBio (RGNX – Research Report) received a Hold rating and price target from Goldman Sachs analyst Paul Choi today. The company’s shares ...